LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

LLY

1,077.57

+1.01%↑

JNJ

230.33

-1.81%↓

ABBV

214.13

-0.92%↓

UNH

379.61

-2.21%↓

AZN

187.76

+0.27%↑

Home・Lista de Ações・Beam Therapeutics Inc

Beam Therapeutics Inc

Abrir

SetorSaúde

29.6 3.64

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

28.71

Máximo

30.22

Indicadores-chave
By Trading Economics
Rendimento	-339M -94M
Vendas	-82M 32M
EPS	-0.91
Margem de lucro	-297.177
Funcionários	522
EBITDA	-362M -102M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+74.27% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-217M 2.9B
Abertura anterior	25.96
Fecho anterior	29.6

Sentimento de Notícias

By Acuity

21%

79%

36 / 345 Ranking em Healthcare

Beam Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de mai. de 2026, 08:24 UTC

Grandes Movimentos do Mercado

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 de mai. de 2026, 21:22 UTC

Ganhos

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:01 UTC

Conversa de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 de mai. de 2026, 14:43 UTC

Conversa de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 de mai. de 2026, 14:15 UTC

Conversa de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 de mai. de 2026, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

25 de mai. de 2026, 12:58 UTC

Conversa de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 de mai. de 2026, 12:56 UTC

Conversa de Mercado

Ganhos

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 de mai. de 2026, 12:34 UTC

Conversa de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 de mai. de 2026, 12:10 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Delivery Hero's Assets Look Strategic -- Market Talk

25 de mai. de 2026, 11:00 UTC

Conversa de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 de mai. de 2026, 10:19 UTC

Conversa de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 de mai. de 2026, 10:05 UTC

Ganhos

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 de mai. de 2026, 10:04 UTC

Ganhos

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 de mai. de 2026, 10:03 UTC

Ganhos

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 de mai. de 2026, 10:02 UTC

Ganhos

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 de mai. de 2026, 10:01 UTC

Ganhos

Tenaga Nasional 1Q Net Up 3.7% on Year

25 de mai. de 2026, 10:00 UTC

Ganhos

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q EPS MYR0.1883

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Rev MYR17.1B

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Net MYR1.1B

25 de mai. de 2026, 09:38 UTC

Conversa de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 de mai. de 2026, 08:55 UTC

Conversa de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparação entre Pares

Variação de preço

Beam Therapeutics Inc Previsão

Preço-alvo

By TipRanks

74.27% parte superior

Previsão para 12 meses

Média 49.91 USD 74.27%

Máximo 80 USD

Mínimo 26 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Beam Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para Beam Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

36 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.